LegalJun 22, 2026, 07:06 AM
Incyte to Record $246M Benefit from CMS Opzelura Rebate Settlement
AI Summary
Incyte Corporation announced an agreement with the Centers for Medicare & Medicaid Services (CMS) to resolve litigation regarding Medicaid rebate rules for Opzelura cream. Under the settlement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi. The company expects to record a one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026, and anticipates improved gross-to-net for Opzelura going forward.
Key Highlights
- Agreement reached with CMS to resolve litigation on Medicaid rebate rules for Opzelura.
- CMS will not apply line extension regulation to Opzelura as if it were a line extension of Jakafi.
- Incyte expects to record a one-time, non-cash benefit of approximately $246 million in Q2 2026.
- Benefit is associated with the reversal of previously established accrual balances through March 31, 2026.
- Company will no longer accrue for potential application of line extension regulations to Opzelura.
- Expects an improvement to Opzelura's gross-to-net on a go-forward basis.
- Company plans to update financial guidance during the next scheduled earnings release.
Price Impact
More from INCY